ClinicalTrials.gg
RecruitingNCT05620784Updated Sep 13, 2023

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

A Phase 3 interventional study of Furosemide in BPH With Urinary Obstruction, BPH and Hematuria, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Northwestern University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Hematuria with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Hematuria · United States.

Planned enrollment
7th of 13
138 · median 138
Started
2023
with 1 other
Phase 3
2 of 20
2 open now
Registered
14th of 20
by date

Among the 20 studies in Hematuria with a site in United States, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 14th registered.

Hematuria

67 studies on the registry are indexed under Hematuria; 16 are open to participants now.

Browse Hematuria studies →

Open to participants now

5 of the 20 studies in Hematuria with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hematuria studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 89 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hematuria with a site in United States, or all of them as a file.
02

Study summary

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .

Read the detailed description

Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration.

This single-center randomized controlled trial is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP). We currently attempt to perform HoLEP as a same-day discharge (SDD) procedure, however one of the main limiting factors in SDD is hematuria. Loop diuretics (furosemide) have been administered at the time of morcellation as a part of our HoLEP pathway to increase post-operative urinary output and reduce clinically significant gross hematuria and clot-formation. The objective of our study will be to assess if SDD rates are non-inferior in those patients who do not receive furosemide diuretics versus those that do.

Patients will be randomized 1:1 to 20mg of IV lasix versus control. Patients and the surgeon/post-operative care team (fellow, residents, and nursing team) will be blinded to the treatment allocation.

03

Conditions studied

  • BPH With Urinary Obstruction
  • BPH
  • Hematuria
  • Same Day Discharge

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males 18 -89 undergoing HoLEP
  • Willing to sign the Form
  • Able to read, understand, and complete patient questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Allergy or to furosemide or other loop diuretic
  • Anuric patients or patients with liver failure
  • Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP
  • Anticipated need for perineal urethrostomy at the time of HoLEP
  • Patient not undergoing catheter removal and voiding trial at Northwestern Memorial Hospital
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Loop Diuretic (Furosemide)

    This group of patients will receive 20mg of IV furosemide during the morcellation phase of their HoLEP.

    Drug: Furosemide

  • No intervention
    Control

    This group of patients will not receive 20mg of IV furosemide during the morcellation phase of their HoLEP.

Interventions

  • 20mg of IV furosemide injection during the morcellation phase of HoLEP

    Also known as: Lasix, Loop diuretic

06

What researchers measure

Primary outcomes

  1. Same-day discharge

    Rate of successful same-day discharge after HoLEP

    Time frame: 90-days

  2. Same-day catheter removals

    Rate of successful same-day catheter removals after HoLEP

    Time frame: 90-days

Secondary outcomes

  1. Adverse medical events (hematuria)

    Rate of unplanned Emergency Department (ED) visits/clinic visits related to bleeding/admission/clot evacuation

    Time frame: 90-days

  2. Adverse medical events (fluid absorption)

    Rate of transurethral resection (TUR) syndrome, vision changes, seizure, hyponatremia, electrolyte abnormality

    Time frame: 90-days

  3. Duration of post-operative hematuria

    (days)

    Time frame: 90-days

  4. Difference in operative efficiency (enucleation, morcellation, and overall)

    (minutes/gram)

    Time frame: 90-days

  5. Length of hospital stay

    (hours)

    Time frame: 90-days

  6. Overall complications

    Clavien-Dindo Classification

    Time frame: 90-days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Parsons JK, Dahm P, Kohler TS, Lerner LB, Wilt TJ. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020 Oct;204(4):799-804. doi: 10.1097/JU.0000000000001298. Epub 2020 Jul 23. PubMed 32698710 ↗
  • Agarwal DK, Large T, Tong Y, Stoughton CL, Damler EM, Nottingham CU, Rivera ME, Krambeck AE. Same Day Discharge is a Successful Approach for the Majority of Patients Undergoing Holmium Laser Enucleation of the Prostate. Eur Urol Focus. 2022 Jan;8(1):228-234. doi: 10.1016/j.euf.2020.12.018. Epub 2021 Jan 4. PubMed 33414073 ↗
  • Kuo RL, Paterson RF, Kim SC, Siqueira TM Jr, Elhilali MM, Lingeman JE. Holmium Laser Enucleation of the Prostate (HoLEP): A Technical Update. World J Surg Oncol. 2003 Jun 6;1(1):6. doi: 10.1186/1477-7819-1-6. PubMed 12818001 ↗
  • Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol. 2006 Apr;175(4):1428-32. doi: 10.1016/S0022-5347(05)00645-2. PubMed 16516015 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jun 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Nov 17, 2022
StartActual
Mar 1, 2023
Primary completionActual
Jun 6, 2023
CompletionEst.
Aug 1, 2024
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05620784
Responsible party
Amy Krambeck (Director of The Division of Endourology & Stone Disease, Northwestern University) — Principal investigator
First posted
Nov 17, 2022
Start date
Mar 1, 2023
Primary completion
Jun 6, 2023
Completion
Aug 1, 2024 (estimated)
Last update
Sep 13, 2023

Study contacts

Nicholas S Dean, MD
Contact
nicholas.dean@northwestern.edu
7806906285
Amy E Krambeck, MD
principal investigator · Northwestern Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion